JP2024523443A5 - - Google Patents
Info
- Publication number
- JP2024523443A5 JP2024523443A5 JP2023578727A JP2023578727A JP2024523443A5 JP 2024523443 A5 JP2024523443 A5 JP 2024523443A5 JP 2023578727 A JP2023578727 A JP 2023578727A JP 2023578727 A JP2023578727 A JP 2023578727A JP 2024523443 A5 JP2024523443 A5 JP 2024523443A5
- Authority
- JP
- Japan
- Prior art keywords
- lyophilized
- sequence
- formulation
- activatable
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163213026P | 2021-06-21 | 2021-06-21 | |
| US63/213,026 | 2021-06-21 | ||
| PCT/US2022/033958 WO2022271544A1 (en) | 2021-06-21 | 2022-06-17 | Use of sucrose, mannitol and glycine to reduce reconstitution time of high concentration lyophilized biologics drug products |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024523443A JP2024523443A (ja) | 2024-06-28 |
| JP2024523443A5 true JP2024523443A5 (enExample) | 2025-06-18 |
Family
ID=82403446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023578727A Pending JP2024523443A (ja) | 2021-06-21 | 2022-06-17 | 高濃度凍結乾燥生物製剤の再構成時間を減少させるためのスクロース、マンニトールおよびグリシンの使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250332251A1 (enExample) |
| EP (1) | EP4359438A1 (enExample) |
| JP (1) | JP2024523443A (enExample) |
| KR (1) | KR20240024929A (enExample) |
| CN (1) | CN117500834A (enExample) |
| WO (1) | WO2022271544A1 (enExample) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04000747A (es) * | 2001-07-25 | 2004-07-08 | Protein Desing Labs Inc | Formulacion farmaceutica liofilizada estable de anticuerpos igg. |
| AU2003293543A1 (en) * | 2002-12-13 | 2004-07-09 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
| EP2458990B1 (en) * | 2009-07-28 | 2016-03-30 | Merck Sharp & Dohme Corp. | Methods for producing high concentration lyophilized pharmaceutical formulations |
| BR112013011176A2 (pt) * | 2010-11-05 | 2020-09-01 | Novartis Ag | métodos de tratamento de artrite reumatoide usando antagonistas de il-17 |
| EP3443346B1 (en) * | 2016-04-13 | 2023-08-30 | Medimmune, LLC | Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents |
| MY200695A (en) | 2016-11-03 | 2024-01-11 | Bristol Myers Squibb Co | Activatable anti-ctla-4 antibodies and uses thereof |
| JOP20190260A1 (ar) * | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| GB201718888D0 (en) * | 2017-11-15 | 2017-12-27 | Ucb Biopharma Sprl | Method |
| TWI897855B (zh) * | 2018-10-26 | 2025-09-21 | 美商免疫遺傳股份有限公司 | Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途 |
| TW202112354A (zh) * | 2019-06-05 | 2021-04-01 | 美商西雅圖遺傳學公司 | 遮蔽抗體調配物 |
-
2022
- 2022-06-17 CN CN202280043695.4A patent/CN117500834A/zh active Pending
- 2022-06-17 WO PCT/US2022/033958 patent/WO2022271544A1/en not_active Ceased
- 2022-06-17 US US18/572,479 patent/US20250332251A1/en active Pending
- 2022-06-17 KR KR1020247001907A patent/KR20240024929A/ko active Pending
- 2022-06-17 EP EP22738290.0A patent/EP4359438A1/en active Pending
- 2022-06-17 JP JP2023578727A patent/JP2024523443A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8795686B2 (en) | Stable, dried rotavirus vaccine, compositions and process for preparation thereof | |
| US9642907B2 (en) | Stabilized liquid rotavirus vaccine composition | |
| RU2695523C2 (ru) | Вакцины против вирусов свиней, стабильные в жидкой форме | |
| FR2742756A1 (fr) | Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation | |
| KR910005888B1 (ko) | 동결건조 b형 간염 왁진의 제조방법 | |
| CA2272245A1 (en) | Stable lyophilized pharmaceutical preparations of monoclonal or polyclonal antibodies | |
| JPH01279843A (ja) | 凍結乾燥ａ型肝炎ワクチン | |
| US20230293662A1 (en) | Compositions, methods and uses for thermally stable human papillomavirus formulations | |
| KR20240046787A (ko) | 지질 나노-에멀젼 입자에 흡착된 mRNA의 동결건조 제제 | |
| BG65314B1 (bg) | Метод за разделяне на варианти на ротавирус и жива атентюирана ротавирусна ваксина | |
| AU2013208693B2 (en) | Compositions and methods for treating viral infections | |
| CN114752703A (zh) | 一种新型冠状病毒核酸的冻干型检测试剂及其制备方法 | |
| JP2023539476A5 (enExample) | ||
| CN102892409B (zh) | 用于保存铝盐佐剂和铝盐-佐剂化疫苗的方法 | |
| CN113521018A (zh) | 一种含有抗her2-药物偶联物的冻干组合物、冻干制剂及其制备方法和用途 | |
| HK1207312A1 (en) | Temperature stable vaccine formulations | |
| KR20200000497A (ko) | Vlp 안정화된 백신 조성물 | |
| JP2023538669A5 (enExample) | ||
| JPS63115825A (ja) | 中和糖タンパク質のペプチド | |
| JP2024523443A5 (enExample) | ||
| CN1050987A (zh) | 用于口服的稳定的免疫原组合物 | |
| JP7085482B2 (ja) | スタフィロコッカス感染症のための凍結乾燥製剤を製造する方法 | |
| CN108379561A (zh) | 一种聚乙二醇化尿酸氧化酶冻干粉剂及其制备方法 | |
| Dong et al. | Thermostability of a trivalent, capsomere-based vaccine for human papillomavirus infection | |
| JP2024521329A5 (enExample) |